Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbing Duan

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Environmental Science & Technology|March 25, 2026
Iron-Based Nanomaterials Enhance Rice Growth and Limit Grain Arsenic Accumulation via Iron Plaque Formation and Rhizosphere ModulationMengshan Tang, Zhiyuan Lv, Jiayi Wang, et al.
Journal of Hazardous Materials|December 2, 2025
Dual regulation of pakchoi-soil systems by zinc oxide nanoparticles under polyethylene microplastics stress: Dose-dependent effects, microbial cascades, and risk propagationKun Zhang, Yawen Zhao, Hongbing Duan, et al.
Biomarkers in Medicine|June 17, 2017
Plasma microRNA-19a as a potential biomarker for esophageal squamous cell carcinoma diagnosis and prognosisYongying Bai, Huayue Lin, Zanxi Fang, et al.
International Journal of Surgery (London, England)|June 15, 2023
Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort studyZhinuan Hong, Jinxin Xu, Zhen Chen, et al.
Journal of Thoracic Disease|December 13, 2023
Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort studyYi Zhang, Guoyi Shen, Rongyu Xu, et al.
JTO Clinical and Research Reports|February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup AnalysisJie Wang, Yi-Long Wu, Shun Lu, et al.
Journal of the National Cancer Center|April 23, 2025
Three-field vs two-field lymphadenectomy in thoracic ESCC patients: a multicenter randomized study (NST 1503)Yousheng Mao, Shuoyan Liu, Yongtao Han, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Environmental Science & Technology|March 25, 2026
Iron-Based Nanomaterials Enhance Rice Growth and Limit Grain Arsenic Accumulation via Iron Plaque Formation and Rhizosphere ModulationMengshan Tang, Zhiyuan Lv, Jiayi Wang, et al.
Journal of Hazardous Materials|December 2, 2025
Dual regulation of pakchoi-soil systems by zinc oxide nanoparticles under polyethylene microplastics stress: Dose-dependent effects, microbial cascades, and risk propagationKun Zhang, Yawen Zhao, Hongbing Duan, et al.
Biomarkers in Medicine|June 17, 2017
Plasma microRNA-19a as a potential biomarker for esophageal squamous cell carcinoma diagnosis and prognosisYongying Bai, Huayue Lin, Zanxi Fang, et al.
International Journal of Surgery (London, England)|June 15, 2023
Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort studyZhinuan Hong, Jinxin Xu, Zhen Chen, et al.
Journal of Thoracic Disease|December 13, 2023
Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort studyYi Zhang, Guoyi Shen, Rongyu Xu, et al.
JTO Clinical and Research Reports|February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup AnalysisJie Wang, Yi-Long Wu, Shun Lu, et al.
Journal of the National Cancer Center|April 23, 2025
Three-field vs two-field lymphadenectomy in thoracic ESCC patients: a multicenter randomized study (NST 1503)Yousheng Mao, Shuoyan Liu, Yongtao Han, et al.
Cancer Communications (London, England)|June 29, 2021
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trialYuankai Shi, Kaijian Lei, Yuming Jia, et al.
Pageof 2